[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"coarctation-of-aorta\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:coarctation-of-aorta":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,46,98,124,156,193],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100603022","impact-of-aortic-geometry-on-vascular-remodeling-after-stent-implantation-in-coarctation-of-the-aorta-100603022",false,"NCT07131111","Impact of Aortic Geometry on Vascular Remodeling After Stent Implantation in Coarctation of the Aorta","Inclusion Criteria:\n\nAge ≥ 12 years.\n\nDiagnosed with native or recurrent coarctation of the aorta.\n\nTranscatheter systolic pressure gradient ≥ 20 mmHg.\n\nBody weight ≥ 20 kg.\n\nAvailability of pre- and post-stenting CT aortography data.\n\nExclusion Criteria:\n\nPatients with obstructive lesion of LVOT or aortic valve dysfunction greater than moderate (requiring surgical intervention)..\n\nPatients with other causes of secondary hypertension.\n\nAssociated complex congenital heart defects (aside from simple septal defects and patent ductus arteriosus)\n\nGenetic syndromes\n\nConnective tissue disorder\n\nHistory of surgery involving the aortic root or ascending aorta.\n\nIncomplete imaging or missing data relevant to the study.",true,"ALL","12 Years",{"count":19,"type":20},50,"ESTIMATED","OBSERVATIONAL","This study aims to assess:\n\n1. Aortic geometrical changes and their relationship to hypertension and cardiovascular events.\n2. Aortic geometrical differences between healthy individuals and patients with repaired coarctation of the aorta.",[24,25,26,27,28,29,30,31,32],"Aortic Geometry","Vascular Remodeling","Coarctation of Aorta","Blood Pressure","Residual Stenosis","CT Aortography","CMR","Aortic Elasticity and Distensibility","Aortic Arch","NOT_YET_RECRUITING","2025-08-12",{"date":36,"type":37},"2025-08-20","ACTUAL",{"date":39,"type":20},"2025-09-01",{"date":41,"type":20},"2026-12-31",{"name":43,"class":44},"Assiut University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":57,"conditions":58,"keywords":83,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":97},"100599630","cardiovascular-risk-in-children-with-chronic-conditions-study-100599630","NCT07086989","Cardiovascular Risk in Children With Chronic Conditions Study","CR3C","Inclusion criteria:\n\n1. Individuals aged between 6 and 25 years;\n2. Diagnosed with a chronic childhood condition\u002Fdisease associated with an increased risk of early cardiovascular disease;\n3. Provided informed consent (if over 18 years old) or had informed consent provided by their legal guardian (if under 18 years old) following appropriate information about the study.\n\nChronic childhood conditions\u002Fdiseases associated with increased risk of early cardiovascular disease are defined according to the 2019 American Heart Association recommendations (https:\u002F\u002Fdoi.org\u002F10.1161\u002FCIR.0000000000000618), as well as other conditions\u002Fdiseases for which at least two large-scale epidemiological studies have demonstrated an increased risk of cardiovascular disease.\n\nExclusion criteria:\n\n1. Severe intellectual and developmental disability;\n2. Decompensated heart failure;\n3. Severe primary immunodeficiency;\n4. Ongoing intravenous chemotherapy;\n5. Infectious diseases posing a public health risk; or\n6. History of regular alcohol or drug use.","6 Years","25 Years",{"count":56,"type":20},300,"Children living with chronic health conditions face a higher risk of developing cardiovascular diseases than their peers, largely due to the accelerated aging of the heart and blood vessels. Although experts recognize this elevated risk and recommend close monitoring and early intervention, the underlying mechanisms driving this phenomenon remain poorly understood. At present, no effective interventions specifically target its root causes.\n\nRecent research shows that both large blood vessels (such as the carotid artery) and small vessels (such as those in the retina) can display early signs of damage decades before clinically apparent heart or vascular disease emerges. This accelerated vascular aging can result from multiple factors - including disease-related processes such as persistent inflammation and metabolic disturbances, treatment-related effects such as chemotherapy or long-term steroid use, and lifestyle changes associated with chronic illness, such as reduced physical activity and altered eating habits. However, it is still unclear how these factors influence the development and progression of vascular changes in children as they grow. Importantly, these changes can be monitored through non-invasive methods, offering a unique opportunity to study at-risk patients many years before overt cardiovascular disease develops.\n\nIdentifying these early changes may enable us to detect and track individuals at heightened risk well in advance of clinical disease. This study aims to deepen our understanding of the causes of increased cardiovascular risk in children with chronic conditions and to lay the groundwork for earlier, more targeted prevention strategies.",[59,60,61,62,63,64,65,66,67,26,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82],"Kidney Transplant","Familial Hypercholesterolaemia","Type 1 Diabetes Mellitus (T1DM)","Type 2 Diabetes Mellitus (T2DM)","Chronic Kidney Disease","Kawasaki Disease","Liver Transplant","Obesity and Overweight","Hypertension","Bone Marrow Transplant","Cancer (Solid Tumors)","Leukemia","Lymphoma","Lipoprotein(a)","Aorta Stenosis","Non Alcoholic Fatty Liver Disease","Dyslipaemia","White Coat Hypertension","Pulmonary Hypertension","Juvenile Idiopahtic Arthritis","Systemic Lupus Erthematosus","Inflammatory Bowel Disease (IBD)","HIV Infection","Transposition of Great Arteries",[84,85,86],"cardiovascular risk","vasculature","children with chronic conditions","RECRUITING","2025-08-04",{"date":90,"type":37},"2025-08-08",{"date":92,"type":37},"2025-04-01",{"date":94,"type":20},"2029-01-31",{"name":96,"class":44},"Semmelweis University",3,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":106,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":109,"phases":110,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":45},"100527653","phase-3-a-study-of-angiotensin-ii-receptor-blocker-on-cardiovascular-remodeling-value-trial-100527653","NCT06150560","A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial)","A Phase III, Randomized, Double-Blind, Placebo Controlled Clinical Trial Evaluating the Benefits and Mechanism Of Action Of Angiotensin-II Receptor Blocker On Cardiovascular Remodeling In Patients With Repaired Coarctation Of Aorta","VALUE","Inclusion Criteria:\n\n* B\u002FS1 hypertension\n* SBP 100-139 average based on 3 office measurements.\n* Age 18 or Older\n* Previous COA Repair\n\nExclusion Criteria:\n\n* Currently on beta blocker (BB) therapy\n* Pregnancy\u002Flactating\n* eGFR\\\u003C30\n* Hyperkalemia (serum potassium \\>5.5mmol\u002FL)\n* Severe Aortic or Mitral valve stenosis or regurgitation\n* Epicardial CAD diagnosis\n* Received antihypertensive medications within the past year","18 Years",{"count":108,"type":20},120,"INTERVENTIONAL",[111],"PHASE3","The purpose of this study is to evaluate the effectiveness and mechanism of action of Losartan in the treatment of coarctation of aorta.",[26,114],"High Blood Pressure","2025-07-30",{"date":117,"type":37},"2025-08-03",{"date":119,"type":37},"2024-04-01",{"date":121,"type":20},"2028-06-01",{"name":123,"class":44},"Mayo Clinic",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":131,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":45},"100370678","nirs-in-congenital-heart-defects---correlation-with-echocardiography-100370678","NCT04106479","NIRS in Congenital Heart Defects - Correlation With Echocardiography","Do Cerebral and Renal Saturations Measured With Near-infrared Spectroscopy Correlate With Echocardiographic Markers of Perfusion and Cardiac Performance in Congenital Heart Disease?","Inclusion Criteria:\n\nA prospective study will be conducted of all newborns with tetralogy of fallot, trucus arteriosus, D-transposition of great arteries, PS, AS, coarctation of the aorta, DILV, AVC, DORV, HLHS, TA and PAIVS consecutively admitted at our institution (Montreal Children's Hospital) neonatal intensive care unit (NICU) from January 2018 to January 2020. Patients with CHD will be compared to a control population of term infants admitted and monitored in the NICU with antenatal suspicion of coarctation, ruled-out postnatally.\n\nExclusion Criteria:\n\nPatients will be excluded if premature less than 34 weeks of estimated gestational age (GA) at birth or if parents do not consent. Parental consent can be withdrawn at any time during the study.","0 Days","7 Days",{"count":134,"type":20},100,"Neonatal patients with congenital heart defects (CHD) have changing physiology in the context of transitional period. Patients with CHD are at risk of low perfusion status or abnormal pulmonary blood flow. Near infrared spectroscopy has been used in neonatal intensive care units (NICU) to measure end-organ perfusion. The investigator plan on monitoring newborns with CHD admitted to the NICU with NIRS and echocardiography during the first week of life and correlate measures of perfusion from Dopplers to cerebral and renal NIRS.",[137,138,26,139,140,141,142,143,144,145,146],"Congenital Heart Defect","Single-ventricle","Atrioventricular Canal","Hypoplastic Left Heart","Transposition of Great Vessels","Interrupted Aortic Arch","Tricuspid Atresia","Pulmonary Atresia","Aortic Atresia","Tetralogy of Fallot","2025-06-12",{"date":149,"type":37},"2025-06-17",{"date":151,"type":37},"2019-10-11",{"date":153,"type":20},"2025-12-01",{"name":155,"class":44},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":16,"minAge":163,"maxAge":164,"enrollmentInfo":165,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":167,"conditions":168,"keywords":178,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":45},"100575109","an-integrated-prenatal-and-postnatal-treatment-model-for-the-treatment-of-newborns-with-critical-congenital-heart-disease-100575109","NCT06768008","An Integrated Prenatal and Postnatal Treatment Model for the Treatment of Newborns With Critical Congenital Heart Disease","Clinical Study of an Integrated Prenatal and Postnatal Treatment Model to Improve the Treatment Effect of Newborns With Critical Congenital Heart Disease","Inclusion Criteria:\n\n1. Full-term infants (gestational age 37-40 weeks): age less than 28 days;\n2. Preterm infants (gestational age greater than 32 weeks but less than 37 weeks): corrected gestational age as neonatal period, age less than 28 days;\n3. Birth weight \\> 1.5 kg;\n4. Fetal diagnosis of congenital heart diseases by ultrasound at 22-26 weeks of gestation, suitable for biventricular repair.\n\nExclusion Criteria:\n\n1. Only suitable for palliative surgery or single ventricle repair;\n2. Associated genetic\u002Fchromosomal abnormalities;\n3. Associated with other severe systemic diseases.","1 Day","28 Days",{"count":166,"type":20},10000,"The purpose of this two-way cohort study was to explore whether an integrated prenatal and postnatal treatment model for neonates with critical congenital heart disease (CCHD) could be effective in avoiding preoperative morbidities, creating an ideal timing for surgery, thereby reducing postoperative in-hospital mortality, and improving surgical prognosis compared with the traditional model of care. In addition, in neonates with CCHD associated with the right cardiac system, the investigators aim to further investigate whether early postnatal cardiac surgery has the potential advantage of obtaining a time window for myocardial regeneration and thus improving myocardial remodeling. The aim of this study is to improve the diagnostic and therapeutic capacity of critical congenital heart disease and to promote the integrated prenatal-postnatal treatment model for clinical use. This will ultimately improve the quality of healthcare services for patients with cardiovascular diseases and lay the foundation for exploring guidelines for the treatment of cardiovascular diseases suitable for China's national conditions.\n\nThe project will be jointly implemented by Beijing Anzhen Hospital , Capital Pediatric Research Institute, and 307 PLA General Hospital. Starting from January 1, 2022, the hospitals will continue to collect hospitalized cases of newborns with CCHD. The integrated prenatal and postnatal model is defined as a definitive diagnosis of CCHD in the fetal period (22-26 weeks), documentation of intrauterine transfer in our obstetrics department, subsequent initiation of an intrapartum or postpartum surgical plan after multidisciplinary consultation, and transfer to the pediatric heart center at the first hour of life, where the child is treated with either postpartum immediate or elective surgery, depending on patient status. For neonates who meet the indications for emergency surgery, surgery is performed immediately after birth. For neonates with non-emergency surgical indications, surgery is performed after birth adjustment to optimal status. The traditional model was defined as postpartum transfer via an outside hospital with routine interventions. The investigators then evaluate surgical prognosis and myocardial regenerative capacity to compare the effects of the two treatment models. This project will validate the advantages of an integrated prenatal and postnatal model over traditional models through real-world research and will improve prognosis in neonates with CCHD.",[169,26,170,144,171,172,173,174,175,142,176,177],"Congenital Heart Disease","Aortic Stenosis","Pulmonary Stenosis","Transposition of the Great Arteries","Truncus Arteriosus","Single Ventricle","Tetralogy of Fallot (TOF)","Hypoplastic Left Heart Syndrome (HLHS)","Total Anomalous Pulmonary Venous Connection",[179,180,181,182,183],"congenital heart disease","Integrated prenatal and postnatal model","neonate","surgery","Myocardium regeneration","2025-01-05",{"date":186,"type":37},"2025-01-10",{"date":188,"type":37},"2022-01-01",{"date":190,"type":20},"2030-12-31",{"name":192,"class":44},"Beijing Anzhen Hospital",{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":16,"minAge":106,"maxAge":201,"enrollmentInfo":202,"targetDuration":204,"studyType":21,"phases":4,"briefSummary":205,"conditions":206,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":45},"100384660","canadian-adult-congenital-heart-disease-intervention-registry-100384660","NCT04288596","Canadian Adult Congenital Heart Disease Intervention Registry","The Canadian Registry for Adults With Congenital Heart Disease Interventions","C-ACHDiR","Inclusion Criteria:\n\n* participants must be 18 years or older referred for intervention for one of five ACHD conditions including diagnostic catheterization for complex ACHD patients (Tetralogy of Fallot, Fontan, and transposition of the great vessels, single ventricle, truncus arteriosus); transcatheter closure of atrial septal defects; transcatheter closure of patent foramen ovale; coarctation of aorta stenting, and percutaneous pulmonary valve implantation.\n\nExclusion Criteria:\n\n* participants below the age of 18\n* participants residing outside of Canada","110 Years",{"count":203,"type":20},9000,"10 Years","The ACHDi Registry study will create a foundational database for adult congenital heart disease interventions. This Pan-Canadian Registry will collect clinical and patient-reported information that will enable the evaluation of care processes and outcomes in five most common ACHDi interventions by enabling prospective and retrospective registry-based studies to answer important clinical practice and policy-relevant questions.",[207,208,146,209,26,141,210],"Atrial Septal Defect","Patent Foramen Ovale","Fontan","Percutaneous Pulmonary Valve Implantation","2020-02-27",{"date":213,"type":37},"2020-02-28",{"date":215,"type":20},"2020-04-01",{"date":217,"type":20},"2030-04-01",{"name":219,"class":44},"University Health Network, Toronto"]